Companies/Nephros, Inc.

Company profile

Nephros, Inc.

NASDAQ: NEPH · Healthcare · Medical - Instruments & Supplies

PublicHQ South Orange, NJCIK 0001196298Reports USD

#550 of 1,394 Healthcare companies by revenue72nd-percentile growth

EA Score

75B+

FH 74DQ 81GM 73SS 60

v0.1 · 65/100 weight · provisional

↑ return on assets, disclosure history · ↓ workforce scale, Piotroski F

Methodology →

Revenue TTM

$19.1M

Rev growth YoY (TTM)

+23.2%

Net income (FY)

$1.2M

Employees

Market cap

$36.9M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$18.8M$18.8M2025

Net income$1.2M$1.2M2025

Operating income$1.1M$1.1M2025

Total assets$13.6M$13.6M2025

Liabilities$3.4M$3.4M2025

Equity$10.2M$10.2M2025

Revenue trend

FY2018 – FY2025 · USD

$5.7M

FY18

$10.3M

FY19

$8.6M

FY20

$10.4M

FY21

$10.0M

FY22

$14.2M

FY23

$14.2M

FY24

$18.8M

FY25

Revenue by segment

Filed disclosures · FY2025

By product

Royalty and Other Revenues51%

Service47%

Other Revenue2%

By geography

Not disclosed.

The read

Nephros, Inc. booked $18.8M in FY2025 revenue, growing 33% year over year — faster than most Healthcare companies we track, at a 6.4% net margin.

Peers · Healthcare

Stablecoin Development Corp.44D KALA BIO, Inc.31D Eikon Therapeutics, Inc. Common Stock——Radnostix, Inc.51D

Key facts

CEORobert Banks

SectorHealthcare

IndustryMedical - Instruments & Supplies

HeadquartersSouth Orange, NJ

ExchangeNASDAQ: NEPH

Employees31

IPO date2004-09-21

Latest filings

8-K2026-06-15 10-Q2026-05-07 8-K2026-05-07 8-K2026-03-27 10-K2026-03-12 8-K2025-11-26 10-Q2025-11-06 8-K2025-08-11

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.